Skip to content

Second generation NNRTIs poised for treatment-naïve studies

Raltegravir takes key step towards European approval

Paediatric Kaletra tablet gains formal US approval

Experts debate how to develop drugs specifically for MDR TB

EACS: Once-a-day Kaletra can be risky

Bevirimat 300mg oral solution dose does well in study

Fosamprenavir: US approves once-daily dose with less ritonavir boosting

Raltegravir receives accelerated approval from the FDA

Roche abandon Biojector 2000 for T-20 administration